224 related articles for article (PubMed ID: 34162136)
1. Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study.
Aryanian Z; Balighi K; Daneshpazhooh M; Karamshahi E; Hatami P; Goodarzi A; Tajalli M; Vance TM
Int Immunopharmacol; 2021 Jul; 96():107755. PubMed ID: 34162136
[TBL] [Abstract][Full Text] [Related]
2. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
[TBL] [Abstract][Full Text] [Related]
3. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
Brown AE; Motaparthi K; Hsu S
Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
5. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months.
Balighi K; Daneshpazhooh M; Akbari Z; Tavakolpour S; Azimi P; Azizpour A
J Dermatolog Treat; 2019 Jun; 30(4):346-349. PubMed ID: 30081690
[No Abstract] [Full Text] [Related]
6. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.
Baum S; Gilboa S; Greenberger S; Pavlotsky F; Trau H; Barzilai A
J Dermatolog Treat; 2013 Dec; 24(6):427-30. PubMed ID: 23521340
[TBL] [Abstract][Full Text] [Related]
7. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
8. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
[TBL] [Abstract][Full Text] [Related]
10. [Rituximab as treatment for refractory pemphigus in Mexican patients].
Cruz-Meza S; Ruiz-Arriaga LF; Barrón-Tapia MT; Estrada-Aguilar L
Rev Alerg Mex; 2021; 68(1):7-11. PubMed ID: 34148324
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.
Snast I; Spitzer L; Hodak E; Levi A; Mimouni D; Leshem YA
Dermatology; 2021; 237(2):179-184. PubMed ID: 32756069
[TBL] [Abstract][Full Text] [Related]
12. Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult- to-treat disease or a consequence of late rituximab initiation?
Balighi K; Hatami P; Sheikh Aboli MJ; Daneshpazhooh M; Ghiasi M; Mahmoudi HR; Aryanian Z
Dermatol Ther; 2022 Feb; 35(2):e15249. PubMed ID: 34910350
[TBL] [Abstract][Full Text] [Related]
13. Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.
Miše J; Jukić IL; Marinović B
Front Immunol; 2022; 13():884931. PubMed ID: 35592312
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
[TBL] [Abstract][Full Text] [Related]
16. Durable remission of pemphigus with a fixed-dose rituximab protocol.
Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
[TBL] [Abstract][Full Text] [Related]
17. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis.
Agarwal A; Hall RP; Bañez LL; Cardones AR
PLoS One; 2018; 13(9):e0198074. PubMed ID: 30252855
[TBL] [Abstract][Full Text] [Related]
18. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
[TBL] [Abstract][Full Text] [Related]
20. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
